Boston Scientific Initiates OPTION Study of Watchman FLX Device for Stroke Risk Reduction Post-AF Ablation

Shots:

• The OPTION study involves assessing of Watchman FLX left atrial appendage closure vs oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) & warfarin in 1,600 patients with non-valvular AF who undergo a cardiac ablation across 130 sites globally
• The OPTION study will have its 1EPs as all cause death, stroke and systemic embolism with primary safety endpoint as non-procedural bleeding @ 36mos.
• The WATCHMAN FLX is a device, designed for simplified implantation, enhancing sealing within the left atrial appendage, and offer physicians to recapture and reposition the device during the procedure and has received CE Mark in Mar’19

Click here to read full press release/ article | Ref: Boston Scientific | Image: Verdict Medical Devices